Myriad Genetics Inc
MYGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$68.90 | Jwy | Sjnfbpct |
Myriad Genetics Earnings: Strong Results Boost Management’s 2024 Outlook and Our Valuation
No-moat Myriad Genetics reported robust second-quarter results that surpassed our expectations. The solid revenue growth indicates strong demand for the company's core offerings, prompting management to revise its full-year 2024 guidance upward.